U.S. Premarket: Roivant Surges 24%
Roivant rose 24% after a Phase 2 trial of a pulmonary arterial hypertension drug developed by its subsidiary, while Novartis fell 12% and quantum computing stocks gained on news of investment under the U.S. CHIPS Act.